Explore published research on cancer, including study methods and limitations.
In a landmark NEJM trial, oral THC prevented chemotherapy vomiting in 80% of completed courses versus 0% for placebo, with no vomiting during subjective highs.
A 1981 critical review found THC showed promise against chemotherapy nausea but identified significant gaps in safety and pharmacological knowledge.
California designed a four-protocol statewide program to study THC dosing for cancer nausea across ages, involving over 200 investigators and including children and elderly patients.
A cannabis derivative performed similarly to standard medication for preventing radiation-induced vomiting. Both drugs were well tolerated with no clear winner.
In 214 cancer patients, THC and prochlorperazine were equally effective against chemotherapy nausea. THC had more side effects, but patients tolerated them and those effects correlated with nausea relief.
A 1983 review found THC outperformed placebo and standard drugs for chemotherapy nausea, with effectiveness linked to the "high." Synthetic cannabinoids nabilone and levonantradol offered additional options.
THC suppressed human natural killer cell activity against tumor cells in lab tests at concentrations as low as 5 micrograms/mL. The effect was dose- and time-dependent.
A cancer patient developed a dangerous lung fungal infection while using illicitly obtained marijuana during chemotherapy, highlighting contamination risks for immunocompromised users.
A survey of over 1,000 oncologists found 44% had recommended illegal marijuana to chemo patients, with a majority favoring prescription availability. They rated smoked marijuana more effective than oral dronabinol.
A 1994 oncologist survey ranked marijuana ninth among antiemetics, with estimated 50% efficacy and 25% adverse effects. Only 6% would prescribe more even if it were legal.
Delta-8-THC completely prevented vomiting in eight children aged 3-13 across 480 cancer chemotherapy treatments over up to eight months, with negligible side effects.
Daily marijuana smoking produced tobacco-like respiratory symptoms, but COPD would likely require 4-5 joints daily for 30+ years. Cancer risk was documented in case reports but not quantified.
A 1997 Annals of Internal Medicine review supported pharmaceutical THC for nausea and appetite but concluded evidence did not support reclassifying crude marijuana as prescribable medicine.
Cannabis cachexia affects two-thirds of advanced cancer patients. Whole cannabis may be better tolerated than THC alone because CBD reduces psychoactive effects without blocking appetite stimulation.
Systematic review of 30 trials finding cannabinoids outperformed conventional antiemetics for chemotherapy nausea (NNT 6) and vomiting (NNT 8), but with notable side effects including dizziness and dysphoria.
Comprehensive review cataloging cannabinoid therapeutic potential across MS, Parkinson's, neuroprotection, pain, and appetite, highlighting non-psychoactive cannabinoids as potentially offering benefits without psychoactivity.
Nature Reviews Cancer paper documenting that cannabinoids inhibited tumor growth in lab and animal studies while being well tolerated, raising the question of anticancer therapeutic potential.
Review of cannabinoid applications in oncology: proven for chemotherapy nausea and appetite loss, with potential for pain, antitumor effects, mood, and sleep in cancer patients.
Lancet Oncology review examined cannabis-cancer relationships across three dimensions: inconsistent evidence for causing cancer, mixed lab results for fighting cancer, and positive evidence for managing cancer symptoms.
Review found marijuana smoking causes airway inflammation, chronic cough, and precancerous cell changes, but epidemiological evidence for COPD and lung cancer remained limited and inconsistent.
Review identifies FAAH and MAGL enzymes as key therapeutic targets. Blocking endocannabinoid breakdown could treat anxiety, cancer, and neurodegeneration by boosting the body's own cannabinoid system.
Cell study found prolonged THC and CBD exposure reduced drug-resistance protein expression in leukemia cells, increasing their sensitivity to the chemotherapy drug vinblastine.
Review shows endocannabinoids can inhibit tumor blood vessel formation, cancer cell migration, and metastasis across multiple cancer types, with a favorable safety profile compared to standard chemotherapy.
Review of preclinical evidence found that cannabinoids showed anti-tumor properties against brain cancers in lab and animal studies, including slowing growth and triggering cancer cell death.
Review found cannabinoids showed promise for managing pain, appetite loss, nausea, and other symptoms in serious illness, with potential to complement and reduce opioid use.
Pooled analysis of 430 lung cancer cases from North Africa found cannabis smoking associated with 2.4x higher risk after adjusting for tobacco, with combined tobacco+cannabis use carrying an 18.2x risk.
Meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects.
In a study of 636 NPC patients and 615 controls across North Africa, marijuana smoking independently elevated nasopharyngeal cancer risk, separate from cigarette smoking effects.
A review found that cannabinoids showed predominantly inhibitory effects on tumor growth, migration, angiogenesis, and metastasis in preclinical studies, though immunosuppressive properties could complicate in vivo effects.
In 177 cancer patients with opioid-refractory pain, THC/CBD spray significantly reduced pain (43% responders vs 21% placebo), while THC alone did not reach significance, highlighting CBD importance in the formulation.
A review highlighted a new focus on cannabinoids' anti-inflammatory effects in cancer treatment, arguing that their ability to reduce chronic inflammation could be as important as direct anti-tumor effects.
Review identified five strategies for making cannabinoid medicines more effective while reducing psychoactive side effects, covering applications from pain to neurodegeneration.
Review found growing preclinical evidence for cannabinoid anticancer effects across multiple cancer types, but contradictory results and unclear mechanisms limit conclusions.
Long-term THC/CBD spray for cancer pain showed sustained relief without dose escalation or tolerance, with improved sleep, pain, and fatigue scores.
Review found clinical evidence for cannabis in cancer symptom management was only partial, with lab-based anti-cancer findings having no clinical research support.
Review found marijuana smoke causes cough and sputum similar to tobacco but does not appear to cause COPD, with mixed and unclear evidence on cancer risk.
Review of cannabis in cancer care covers established uses (chemotherapy nausea, wasting) and emerging potential for cancer pain (possibly synergistic with opioids) and preclinical antitumor effects.
Review of evidence across 13 state-approved medical marijuana conditions found insufficient evidence for most, with the strongest support for chronic pain and muscle spasticity.
Clinical review found strongest evidence for cannabinoid pharmaceuticals in chemotherapy-induced nausea and AIDS-related appetite loss, with more limited cancer pain data.
Review found CBD and other non-psychoactive cannabinoids inhibited multiple cancer types in animal models through diverse mechanisms and enhanced standard chemotherapy drug activity.
Review found cannabinoids may counter chemotherapy-induced nausea, bone loss, kidney damage, heart damage, pain, and insomnia, based on preclinical and early clinical evidence.
Review mapped non-psychoactive cannabinoid strategies for cancer treatment, including CB2-selective agents and enzyme inhibitors from both cannabis and non-cannabis plants.
Cochrane review of 23 trials found cannabinoids better than placebo for chemotherapy nausea (RR 5.7) and preferred by patients, but no comparison with modern anti-emetics exists.
A clinical review found cannabis helps cancer patients with pain, nausea, appetite, and neuropathy, with preclinical data hinting at possible anti-tumor effects that lack clinical trial confirmation.
A review found medical marijuana shows promise for cancer symptoms with preclinical anticancer signals, but evidence-based dosing is lacking and legal barriers hinder research.
Cannabinoids modestly reduce cancer pain and are useful backup antiemetics, dronabinol improves taste disturbances, and preclinical data show anticancer potential through multiple mechanisms.
A practical oncology guide describes how cannabinoid therapies can address pain, nausea, and appetite loss in cancer patients at all disease stages, potentially reducing the need for multiple other medications.
Review of dronabinol for chemotherapy-induced nausea found it most useful as a second-line or add-on option when standard antiemetics fail, with evidence supporting combination with ondansetron or prochlorperazine.
Review finds cannabis smoke causes bronchitis, may lead to pneumonia and airway obstruction, and poses a potential but inconclusive lung cancer risk with long-term heavy use.
Review of five clinical studies found some evidence that THC and CBD formulations reduce cancer pain, with effective doses as low as 2.7mg THC plus 2.5mg CBD, but the evidence base remains small.
Dispensary study of 217 patients finding younger medical cannabis users consume more and show more problematic use than older users, with early initiation as a key risk factor.
Review showing cannabinoids provide established palliative benefits for brain tumor patients (pain, nausea, anxiety) and demonstrated 50-95% tumor regression in animal glioma studies, with synergistic effects in combination therapies.
Review of how the endocannabinoid system controls immunity, finding widespread expression in immune cells with generally immunosuppressive effects that create both therapeutic opportunities and safety considerations.
Lab and animal study found that the CB1 receptor blocker rimonabant inhibited a major cancer-promoting pathway and reduced colon cancer tumor growth in mice.
Review finding the strongest evidence for cannabis in cancer care is for nausea and pain, with emerging evidence for appetite, sleep, and anxiety, plus preclinical anti-cancer effects.
Review of dronabinol (synthetic THC) for appetite loss: FDA-approved for HIV/AIDS since 1985, new oral solution since 2016, but no cancer indication despite clinical need.
Whole-plant cannabis extract outperformed pure THC against three breast cancer subtypes in lab and animal models, with different mechanisms suggesting a genuine entourage effect.
Review finds the endocannabinoid system is involved in several ENT conditions, with therapeutic potential for pain, inflammation, and head/neck cancers alongside known risks from cannabis smoking.
Comprehensive review cataloged six approved cannabinoid medications and evidence across pain, epilepsy, cancer, neurodegeneration, PTSD, anxiety, and addiction, spanning the full endocannabinoid system.
Review found cannabinoids show preclinical anti-inflammatory and anti-tumor effects relevant to IBD and colorectal cancer, but clinical evidence remains limited to questionnaires and small studies.
Review found smoking cannabis has not been proven to cause lung cancer, while noting emerging therapeutic potential for chemo-related nausea and cancer pain. Better studies needed.
Survey of 1,987 cancer patients found 43% had ever used cannabis and 18% used it recently, mostly for pain and nausea. Only 10% got it from medical dispensaries; 80% got it from friends.
Animal study found THC worsened chemotherapy-induced drops in white blood cells but protected against liver enzyme elevation, suggesting complex drug interactions.
Review of preclinical evidence shows cannabinoids can kill cancer cells and inhibit tumor growth through multiple mechanisms, but also notes cases of cancer stimulation and the need for clinical trials.
Oncologist argues cancer doctors should recommend cannabis for its ability to simultaneously address pain, nausea, appetite, mood, and sleep - a rare multi-symptom intervention in palliative care.
Lab study found cannabis smoke triggered DNA damage, impaired immune defenses, and caused inflammatory responses in human airway cells strikingly similar to tobacco smoke.
Cancer patients in Minnesota's medical cannabis program reported significant improvement across all 8 tracked symptoms, with 27-50% achieving lasting clinically meaningful reductions and only 10.5% reporting side effects.
A systematic review of cannabis pharmacology in cancer found only 18 relevant studies and virtually no absorption data, revealing a critical gap in dosing knowledge for this patient population.
Among 232 Italian cancer patients, 81% knew about medical cannabis but only 2% learned from healthcare professionals, while 34% had considered using it, revealing a clinician communication failure.
Cannabinoids reduced GVHD and improved survival in transplanted mice but also slowed immune cell recovery, highlighting a complex therapeutic tradeoff.
Comprehensive review of CBD's anti-cancer properties, documenting multiple mechanisms of action from lab studies to early clinical evidence.
Review finds reasonable evidence for cannabis in cancer-related nausea, appetite loss, and pain, with promising data for neuropathy and sleep issues.
Review of cannabinoids for chemotherapy nausea highlights CBD's non-psychoactive antiemetic potential through serotonin inhibition, alongside THC's established efficacy.
Study of 17 cannabis strains found terpenoids enhanced cannabinoid anti-cancer activity only when naturally co-occurring in the same strain, supporting strain-specific entourage effects.
Cancer patients in Georgia with legal medical marijuana cards reported cannabis as helpful for pain but struggled with access (68%) and legality concerns (64%).
Review confirms cannabis helps with cancer symptoms like nausea and pain but notes that promising antitumor effects in lab studies remain unproven in humans.
Review of non-THC cannabinoids in cancer finds preclinical evidence of anti-tumor effects through multiple mechanisms, but no clinical confirmation yet.
Review finds cannabis helps cancer symptoms but raises concern that its immune-dampening effects could interfere with immunotherapy and bone marrow transplants.
Phase II crossover trial found oral THC:CBD capsules nearly doubled complete response for refractory chemo nausea (25% vs 14%), with 83% of patients preferring cannabis to placebo despite more side effects.
Study of 45 brain tumor patients found cannabinoid receptor expression increased with tumor grade, with CB2 particularly elevated in blood vessels of high-grade astrocytomas.
Canadian cancer patient surveys found cannabis use increased 26% after recreational legalization, but access problems also doubled, mainly because preferred products like edibles were not legally available.
In vitro study found pure CBD matched or exceeded commercial CBD oils at reducing cancer cell viability, with some oils appearing to protect cancer cells.
Scoping review found only 8 studies on cannabis during radiation therapy, with possible benefits for anxiety and long-term symptoms but 6 of 8 at high bias risk.
Review of how the endocannabinoid system modulates immune function — suppressing inflammation and showing anti-tumor effects in preclinical models.
THC and CBD synergistically killed pediatric brain tumor cells in the lab through multiple mechanisms, but failed to improve survival in mouse brain tumor models, highlighting the gap between lab and clinical results.
Cannabinoid receptors (CB1 and CB2) are found on nearly all immune cell types within tumors. Activating these receptors can modulate cancer-related immune responses, opening potential therapeutic avenues.
An NCI workshop found strong evidence for cannabinoids treating chemo nausea and some evidence for cancer pain, but highlighted underappreciated risks including infections, drug interactions, and the challenge of Schedule I research barriers.
A systematic review found only five studies on cannabis and head and neck cancer, none with standardized dosing. No conclusions about benefits or harms could be drawn from this extremely limited evidence base.
Survey of 1,485 medical cannabis patients in Michigan found that the 72 with cancer used less cannabis, less often, and were less likely to smoke it than non-cancer patients.
Chart review of 45 gynecologic cancer patients on medical marijuana found 71% reported symptom improvement, with nausea responding much better (>70%) than pain (36%).
Interviews with 10 parents revealed families pursued medical cannabis for children with cancer or epilepsy out of desperation, relying on social media and peers rather than healthcare providers for information.
Lab study found THC reduced glioblastoma cell proliferation through the GPR55 receptor rather than CB1/CB2, and CBD unexpectedly abolished this anti-tumor effect.
All 10 of the most-viewed YouTube videos about THC oil for skin cancer were rated poor quality and misleading, yet nearly all viewer comments were positive or neutral.
Lab study finds specific cannabis extract fractions kill glioblastoma cells, inhibit migration and invasion, and prevent colony formation in multiple cancer models.
Ecological analysis finds US states with higher cannabis use and legal cannabis have higher pediatric leukemia rates, though the study design cannot prove individual-level causation.
Pilot RCT of 30 stage IV cancer patients found medical cannabis via state program was feasible, well-tolerated, and showed trends toward reduced opioid use and better pain control.
Systematic review of 36 RCTs found cannabinoids better than placebo but not superior to other antiemetics for chemo-induced nausea, leading MASCC to find insufficient evidence for recommending cannabinoids for GI symptoms in cancer.
A pilot study of nanoparticle THC/CBD spray in 25 advanced cancer patients showed acceptable bioavailability, general safety, and preliminary pain relief, especially for bone metastases.
A survey of 342 terminally ill medical cannabis patients found very low hospice enrollment, suggesting cannabis may serve as an alternative rather than complement to end-of-life care.
Systematic review of 52 studies found some positive cannabis effects on palliative care symptoms, but all evidence was rated very low to low quality.
A CBD-rich cannabis extract killed human pancreatic cancer cells in 3D models through apoptosis pathways that the standard drug gemcitabine alone did not activate.
CBD combined with a ginseng compound in nanoparticles achieved 82% tumor inhibition in breast cancer mice with good tolerability.
Review of 77 published case reports found only 14% provided strong evidence for cannabis anticancer effects, with 81% rated weak and no supporting clinical trial data.
Marijuana causes bronchitis but the evidence suggests it does not cause COPD and probably does not cause lung cancer, a distinctly different pattern from tobacco.
Among 1,472 bladder cancer patients, marijuana use (25%) was not linked to recurrence, while tobacco smoking duration strongly predicted cancer return.
Topical 20% CBD oil resolved both biopsy-confirmed squamous cell carcinoma and lichen simplex chronicus on a 64-year-old woman's hands.
Lab testing of 25 high-THC cannabis extracts found huge variation in anti-cancer and anti-inflammatory effects, with specific terpenes like terpinene and p-cymene predicting better outcomes.
Mouse study identified CB2 cannabinoid receptors in skin immune cells as the mechanism for suppressing chemotherapy-induced nerve pain, working through a peripheral pathway that avoids psychoactive effects.
Review found published cases supporting cannabis safety for chemotherapy nausea in children and preclinical evidence of anti-cancer effects on pediatric tumors, but called for more research.
Cancer patients taking 300 mg/day CBD showed reduced early peripheral neuropathy symptoms during chemotherapy, with particular benefit seen in vibrometry scores and cold sensitivity.
Survey of 2,839 Danish cancer patients found 17% had significant neuropathy. Cannabis users were nearly twice as likely to report high symptom burden, though directionality is unclear.
Survey of 122 Canadian pediatric oncologists found 86% saw cannabis potential for nausea, 72% for pain, and 67% for appetite in children with cancer. Nearly all wanted more research.
Survey of 45 NZ oncology doctors found 84% had patients request cannabis prescriptions. 98% knew of patients using illicit cannabis. All were willing to prescribe properly developed products.
Advanced bile duct cancer patients in Thailand receiving medical cannabis survived 5.7 months vs. 0.8 months with standard care — dramatic but needs randomized trial confirmation.
Lab study found cannabinoid formulations diminished tamoxifen's effectiveness against breast cancer cells, with recreational cannabis ratios showing the largest effect.
Review found smoking marijuana causes chronic bronchitis symptoms but no significant FEV1 decline, and most studies have not linked it to lung cancer.
Scoping review of 163 studies found cancer patients use medical cannabis mainly for nausea, pain, and appetite, with oils as the most common form.
Survey of 612 breast cancer patients found 42% used cannabis, mostly during active treatment, with only 39% telling their doctors and half believing cannabis could treat cancer.
Mouse study found THC weakened PD-1 immunotherapy by suppressing T-cell function through the CB2 receptor. In human cancer patients, higher endocannabinoid levels were linked to worse survival.
Survey of 267 cancer patients found 26% used cannabis, reporting benefits for sleep, nausea, and pain but worse overall symptoms compared to non-users.
JAMA Oncology study of 58,000+ cancer patients found medical marijuana legalization was associated with reduced opioid dispensing and fewer pain-related hospital visits.
Survey of 46 gynecologic cancer patients found 37% used cannabis for pain, anxiety, and insomnia, mostly without prescriptions or doctor involvement.
Cell culture study found CBD and cannabis extracts reduced the effectiveness of platinum chemotherapy drugs by decreasing how much drug accumulated inside cancer cells.
Systematic review of 19 studies (1,927 pediatric cancer patients) found cannabinoids commonly used for chemotherapy nausea with no serious adverse events, but dosing evidence remains insufficient.
MASCC systematic review of 15 RCTs found no high-quality evidence for cannabis treating anxiety, depression, or insomnia in cancer, though sleep showed some promise.
A chart review of elderly cancer patients found no significant improvement in pain, nausea, appetite, insomnia, or anxiety scores after starting medical cannabis.
Review argues epigenomic evidence links cannabis exposure to birth defects, cancer, and accelerated aging through DNA methylation disruption across generations.
Review found cannabis may help brain tumor patients with nausea, pain, appetite, and seizures, but standardized dosing guidance and clinical trials are lacking.
Review found cannabinoids target multiple tumor microenvironment components to fight cancer, with several clinical trials now testing these effects in patients.
Crossover RCT found 1:1 THC:CBD oil significantly reduced chemotherapy-induced nausea in 54 gynecologic cancer patients, though dizziness was common.
Single-cell sequencing study found CBD reprogrammed tumor macrophages and enhanced anti-PD-1 immunotherapy response in a colon cancer mouse model.
Survey of 1,220 cancer patients found Black patients less likely to use opioids and 2.5x more likely to view cannabis as more effective, though socioeconomic factors partly explained the difference.
Arkansas data showed cancer patients with medical marijuana cards had 24% lower odds of antiemetic overuse during chemotherapy, suggesting cannabis may support more appropriate prescribing.
Survey found 41% of cancer patients used cannabis during active treatment, with depression and pain as top reasons, and 13% unsure what cannabinoid they were consuming.
First ASCO guideline on cannabis in cancer advises against using it as a cancer treatment outside trials, but notes it may help with chemotherapy nausea that does not respond to standard antiemetics.
Comprehensive review maps cannabinoid drug interactions across epilepsy, cancer, MS, and pain — CYP450 inhibition by CBD and THC can significantly alter blood levels of co-administered medications.
First study to test CBD-CAR T cell interaction found CBD reduced proliferation through apoptosis but preserved cancer-killing function and cytokine secretion, suggesting a complex but not necessarily harmful interaction.
Scoping review of 152 studies found nervous system, psychiatric, and GI effects were the most common cannabis-related adverse events in cancer patients, with significant under-reporting across the literature.
Lab study found cannabinoids preserved 70-89% of neuron viability (vs. 40% with chemo alone) and limited axon shortening to 23-44% (vs. 63%), suggesting potential for preventing chemotherapy-induced nerve damage.
Meta-analysis of 15 studies found medicinal cannabis had no effect on depression, anxiety, or stress in cancer patients, but increased appetite 12-fold. Higher THC doses doubled the likelihood of anxiety events.
Blocking the CB2 cannabinoid receptor in mice with glioblastoma improved survival from 28 to 40+ days by reducing immunosuppressive macrophages and boosting cancer-killing T cells in the tumor.
Phase II/III RCT of 147 cancer patients found THC:CBD capsules tripled complete response for chemotherapy nausea from 8% to 24% versus placebo, with manageable side effects.
Screening of 182 palliative care cancer patients found none met high-risk criteria for drug dependence, suggesting substance use screening may not be warranted in this population.
A review found CBD shows anti-cancer properties through multiple molecular pathways that trigger cancer cell death.
Among 15,014 matched cancer surgery patients, cannabis use disorder was not independently associated with worse overall outcomes, though kidney injury was slightly elevated.
Study found most online cannabis health content accessed by Thai breast cancer survivors was poor quality, with alternative medicine providers producing the most misleading information.
A cancer patient who failed 5 standard antiemetics became the first known NHS-reimbursed recipient of cannabis flowers for chemotherapy nausea.
Lab study found two cannabinoid receptor-activating compounds killed glioma cancer cells while sparing normal brain cells, working through the PI3K/Akt pathway.
Population study found glioblastoma patients with cannabis use disorder had more surgical complications (32% vs 15%) and neurologic problems at follow-up, challenging claims of cannabis neuroprotection.
National analysis of 1.6 million urologic cancer surgeries found CUD prevalence increased 7-fold (2003-2014) and was linked to 31% longer stays and 33% higher costs, but not more complications.
Scoping review of 35 studies found cannabinoids in cancer care most studied for nausea/vomiting (77%), with far less evidence for appetite, pain, and tumor effects.
CBD reduced the cancer-killing ability of activated NK cells against tumors with high Hsp70 expression by suppressing key immune mediators like interferon-gamma and granzyme B.
Review outlines how medicinal cannabis could protect gut mucosal barriers during cancer treatment, potentially addressing the cascade of symptoms from mucositis through the endocannabinoid system.
Hemp extract reduced chemotherapy-induced nerve pain in rats through multiple pathways including inflammation, neural signaling, lipid metabolism, and gut microbiota, revealed by multi-omics analysis.
Despite fewer toxicants in vapor, cannabis vaping triggered the same inflammatory, cancer, and stress gene pathways in lung cells as smoking — questioning the harm reduction narrative at the molecular level.
Analysis of 19,460 older males found exclusive psychedelic use associated with higher prostate cancer odds, while cannabis co-users had significantly lower odds than psychedelic-only users.
Systematic review of 40 studies found cannabis use did not meaningfully change immune parameters in clinical settings, providing some reassurance for cancer patients using cannabis during immunotherapy.
Survey of 100 brain tumor patients found 51% had used cannabis, with 19% using it for tumor-related symptom relief, favoring CBD over THC.
Study of 854 Ohio cancer patients found higher cannabis (19% vs 13%) and opioid (30% vs 21%) use among those in socially disadvantaged areas, with no rural-urban differences.
Survey of 719 cancer survivors found about one-third used cannabis, with most disclosing to healthcare providers and wanting more information about cannabis.
Meta-analysis of over 10,000 papers found scientific support for medical cannabis in cancer treatment was 31x stronger than opposition, spanning symptom management and potential anticarcinogenic effects.
Cancer patients had lower baseline endocannabinoid levels, but 30 minutes of moderate exercise boosted endocannabinoids in both cancer patients and healthy controls — along with increased happiness.
Meta-analysis of 26 RCTs found cannabinoids beat placebo for chemo nausea, but nearly all studies predate modern antiemetics, leaving their current role unclear.
Pooled analysis of 684 cancer patients found cannabinoid use during dual immunotherapy was safe and associated with improved progression-free survival by one measure.
A population-level claims analysis found cannabis abuse/dependence associated with 2.8 to 4.2 times higher risk of bladder, kidney, and prostate cancer, even after matching on tobacco use and other risk factors.
CBD treatment of chronic myeloid leukemia cells triggered over 3,400 gene expression changes at both 4 and 12 hours, affecting oxidative stress, p53-mediated cell death, immune signaling, and metabolic pathways.
A systematic review found CBD targets pancreatic cancer through multiple mechanisms and enhances chemotherapy in lab studies, but no clinical trials have been conducted.
A systematic review of 19 studies found CBD killed lung cancer cells through multiple pathways, inhibited metastasis, boosted immune response, and enhanced cisplatin and radiation effectiveness.
A review of 16 studies found CBD fought liver cancer through multiple mechanisms including a specific inflammatory cell death pathway, and enhanced the effectiveness of standard drugs sorafenib and cabozantinib.
A systematic review found CBD fights gastrointestinal cancers through multiple mechanisms including cell death induction, growth inhibition, and potential enhancement of conventional chemotherapy.
Phase 2 trial found CBD reduced aromatase inhibitor joint pain in 44% of breast cancer patients, with an average 2.36-point improvement among completers.
Survey found nearly half of breast cancer patients used CBD, mainly for pain and insomnia, with mixed self-reported results.
Pediatric palliative care cannabis clinic saw reduced hospitalizations and polypharmacy across 46 patients.
Cancer survivors with four or more adverse childhood experiences had four times the odds of cannabis use, pointing to early trauma as a key factor in substance use patterns during survivorship.
CBD inhibited EGFR signaling in triple-negative breast cancer cells and doubled their susceptibility to natural killer cell attack by upregulating the FAS death receptor.
Cannabis smoking clearly causes bronchitis symptoms and impairs lung immune function, but decades of research have failed to establish a consistent link to lung cancer despite the presence of known carcinogens in the smoke.
A 1:5 CBG:Phytol combination reduced bile acid-induced DNA damage and mutagenicity in esophageal cells, while CB1 receptor expression correlated with esophageal cancer progression in patient tissue.
Pilot trial of 12 women found oral cannabis capsules (100 mg CBD/5 mg THC TID) did not outperform placebo for chemotherapy-induced nerve pain.
A double-blind trial of 144 cancer patients found THC:CBD oil didn't improve overall symptoms vs. placebo—but pain scores did improve specifically.
After medical marijuana dispensaries opened, cancer surgery patients were less likely to receive strong opioid prescriptions—but just passing the law wasn't enough.
Preclinical study found cannabichromene killed pancreatic cancer cells through multiple death pathways (apoptosis and ferroptosis) via TRPV1 and CB2 receptors, with tumor inhibition confirmed in mice.
Meta-analysis of 6 studies with 15,000+ participants found marijuana use associated with 34% lower oral cancer risk, though authors caution about methodological limitations.
A systematic review of 32 studies found cannabinoids often outperformed outdated antiemetics and placebo for chemo nausea, but only one study compared them to modern standard-of-care treatment.
Among 22,763 cancer patients, cannabis dependence showed no association with mortality, while alcohol and opioid dependence were significant predictors of death even after adjusting for tumor stage.
CBD blocked metastasis-promoting EMT in pancreatic cancer cells by inhibiting the lncRNA MALAT1 and PI3K/Akt/mTOR signaling, and synergized with gemcitabine chemotherapy in 3D tumor models.
A survey of 24 pediatric cancer patients in a medical cannabis program found most reported symptom relief for nausea, appetite, and pain with minimal side effects.
A JAMA Health Forum study of 3 million cancer patients found medical cannabis dispensary openings linked to 41 fewer patients per 10,000 receiving opioid prescriptions and shorter supply durations.
Advanced cancer patients vaporizing cannabis for appetite reported eating benefits and tolerated psychoactive effects well—some even enjoyed them.
In a mouse model of pancreatic cancer, CBD alone extended survival and altered gut bacteria and bile acid metabolism, while THC and the THC-CBD combination did not improve outcomes.
Five waves of national data show cannabis use among cancer patients rose at the same rate as the general population (55-60%) from 2013-2019, regardless of state legalization status.
Lab study provides first evidence that CBD suppresses HLA-G, a molecule tumors use to hide from the immune system, in choriocarcinoma cells.
Review finds THC and CBD show multiple anticancer mechanisms against cervical cancer in preclinical studies, with nanotechnology delivery and combination therapies enhancing potential.
First study of cannabis use in stem cell transplant patients found use shifted from smoking to pharmaceutical products, with increased provider engagement post-transplant.
CBD selectively killed cervical, breast, and colon cancer cells in the lab while sparing normal cells, with colon cancer cells showing the highest sensitivity.
An Ontario study of 11.6 million people found that individuals hospitalized for cannabis use disorder were nearly 3 times more likely to die within 5 years, with especially high risks for suicide and trauma.
Cancer survivors in pain were more likely to use cannabis and cigarettes but less likely to drink—suggesting pain drives specific self-medication choices.
Prospective study of 150 young lung cancer patients found 39% smoked both cannabis and tobacco, with dual smokers showing more aggressive cancers and emphysema than tobacco-only smokers.
Survey of 84 cancer patients found 15.5% believed cannabis can cure cancer, with Hispanic/Latino patients 6.5 times more likely to hold this belief. Patients wanted oncologist guidance but perceived them as unknowledgeable.
Including patients and carers in designing a cannabis trial for cancer anorexia improved study design, recruitment, and real-world relevance.
Six unique challenges of running cannabis trials in palliative care—from legislation to product variability to compassionate access—drawn from real trial experience.
Among 1,962 cancer patients, higher CBD doses and swallowed products were associated with the best anxiety improvement—while depression responded mainly to how cannabis was taken.
Among 1,962 cancer patients in Minnesota's medical cannabis program, higher CBD doses were linked to better sleep improvement (1.87 points on 0-10 scale), while THC showed no consistent sleep benefit.
Mini-review summarizes preclinical evidence that cannabinoids can inhibit tumor growth, trigger cancer cell death, and suppress blood vessel formation, though clinical translation faces major challenges.
Data from two randomized controlled trials showed that medicinal cannabis (CBD alone or THC/CBD) did not cause liver enzyme elevations in 287 cancer patients over 28 days at doses up to 600 mg CBD per day.
CBD reduced HPV-positive head and neck tumors in mice by enhancing immune cell infiltration through MAPK pathway activation, with no effect in immune-deficient animals, proving the anti-tumor mechanism is immune-dependent.
Mendelian randomization study found no causal link between cannabis use disorder and any cancer type, while opioid use disorder showed potential associations with bladder cancer and leukemia.
Systematic review of 22 medicinal plants for chemotherapy-induced nausea found cannabis, ginger, and turmeric had the strongest evidence for multi-targeted antiemetic and chemosensitizing effects.
Lab study found a cannabinoid product killed papillary thyroid cancer cells by activating the tumor suppressor p53 and suppressing cancer-promoting genes BCL-2 and c-Myc.
Survey of 350 Australian cancer patients found 19% used medical cannabis, mostly for pain. Only 28% of users believed the evidence was high quality, and most got information from non-clinical sources.
Lab experiments found a 3:1 CBD:THC combination killed ovarian cancer cells more effectively than either cannabinoid alone through apoptosis and autophagy.
A survey of 237 oncologists found 68% believed cannabis could benefit patients, but only 23% felt knowledgeable and 15% had formal training.
CBC and CBG killed glioblastoma cells in vitro, identifying GPR55 and PINK1 as potential therapeutic targets.
Two elderly patients with advanced liver cancer experienced complete tumor regression after taking cannabis oil for symptom relief — remarkable but uncontrolled case reports that highlight the need for clinical trials.
A study of 27 cancer survivors found CBD (up to 300 mg/day) improved nerve damage symptoms, and adding exercise further enhanced pain relief, mobility, and quality of life over 4 months.
A review finds cannabinoids help cancer patients tolerate immunotherapy side effects but may reduce its anti-cancer effectiveness through CB2-mediated immunosuppression — recommending CBD/CBG over THC during treatment.
A pilot RCT found that a digital education program significantly increased oncology nurses' intention to support safe cannabis use in young adult cancer patients, with 89% completion rates.
A survey of 1,003 cancer survivors found no racial disparities in cannabis use or provider discussions — Black patients who used cannabis were actually the most comfortable discussing it with doctors.
Cannabis vapor activated cancer, inflammation, and oxidative stress genes in human lung cells—without triggering DNA damage, suggesting a unique harm mechanism.
Survey of 2,602 cancer patients finds 1 in 4 use cannabis — primarily for sleep, with higher use among Stage 4 and chemotherapy patients, using multiple consumption methods.
Lab study shows CBD and CBG alter melanoma cell membranes, boost endocannabinoid levels, and reduce inflammatory signals — effects enhanced when combined with UVA radiation.
Review of 16 studies found medical cannabis may improve pain, sleep, appetite, mental health, and reduce opioid use in cancer patients — promising but in need of more rigorous clinical trials.
Case report: 27-year-old cancer survivor completely replaced 120mg/day opioids with medical cannabis within 4 weeks, maintaining pain control at VAS 2-3 with unexpected resolution of a chronic infection over 9 months.
Systematic review shows CBD has multi-target anti-cancer activity — inhibiting growth, triggering cell death, blocking spread, and modulating immunity — but almost all evidence is preclinical and clinical trials are urgently needed.
Survey of 1,089 Canadians found symptom relief and daily functioning matter most when considering medical cannabis for cancer.
Mouse study reveals endocannabinoid-metabolizing enzymes help colon tumors evade the immune system; blocking the pathway improved immunotherapy.
Non-psychoactive hemp seed extract slowed colorectal cancer cell growth by triggering metabolic stress; adding an autophagy inhibitor boosted the effect by 30%.
Review finds cannabinoids modulate autophagy in oral tissues via mTOR/AMPK pathways, with potential for oral cancer and periodontal disease.
Qualitative study found cancer patients overwhelmed by dispensary product variety, using imprecise dosing and frequently switching between multiple administration routes.
CBD prevented precancerous colorectal growths in two mouse models by targeting EEF1B2 to suppress immune-blocking cells, enabling stronger anti-tumor immune responses.
Review mapped how cannabinoids interfere with drug metabolism through CYP450 enzymes, potentially altering effectiveness of antidepressants, blood thinners, opioids, and more.
Review finds preclinical evidence supporting cannabinoid antitumor activity against skin cancers through multiple mechanisms, with topical CBD formulations as a promising delivery approach.
Review explores how medical cannabis could address the severe symptom burden in head and neck cancer, including pain, nausea, cachexia, and difficulty swallowing.
Survey finds 89% of cancer care providers believe cannabis manages symptoms but only 15% feel knowledgeable, revealing a critical education gap in oncology.
Review details how cannabinoids activate autophagy-mediated cell death in glioblastoma, with promising preclinical evidence and early clinical safety data.
Lab study found CBD killed kidney cancer cells but equally killed normal kidney cells, lost effectiveness in the presence of serum proteins, and required concentrations far beyond clinically achievable levels.
Lab study found the body's own cannabinoids (anandamide and oleamide) selectively killed glioblastoma cells by disrupting mitochondrial function through PPAR-gamma receptors, while sparing normal brain cells.
First preclinical evidence that 14 days of inhaled CBD pretreatment significantly reduced glioblastoma tumor growth in mice by modulating immune checkpoint markers.
CBD reduced CD47 (an immune evasion signal) on leukemia cells and triggered apoptosis through VDAC-1 oligomerization, a specific mitochondrial mechanism.
CBD inhibited melanoma growth and metastasis in mice by activating PPARgamma-TET1 to demethylate LRSAM1, a newly identified anti-cancer gene.
Review found cannabinoid receptor agonists reduced chemotherapy-induced organ damage in preclinical studies by suppressing inflammation and oxidative stress.
Pilot RCT of 32 pancreatic cancer patients found medical cannabis feasible through state program partnership, with promising but non-significant improvements in pain, appetite, and insomnia.
Randomized trial found topical THC and CBD balms well tolerated for breast cancer treatment-related joint pain, with 86% reporting improvement and THC balm outperforming CBD.
Landmark Nature Medicine study showing THC caused brain tumor regression in rats through a ceramide-mediated cell death pathway that selectively killed cancer cells while sparing normal tissue — opening the field of cannabinoid anticancer research.
Harvard-affiliated preclinical study showing CBD selectively kills both triple-negative and ER-positive breast cancer cells through coordinated autophagy and apoptosis while sparing normal mammary cells.
NEJM trial showing nabilone (synthetic cannabinoid) was dramatically superior to standard anti-nausea drug for chemo patients — 80% vs 32% response rate. Among the earliest RCTs of any cannabinoid, co-authored by cisplatin pioneer Larry Einhorn.
First randomized trial of THC+CBD for brain cancer showed 83% vs 44% one-year survival — encouraging but from only 21 patients. The ARISTOCRAT follow-up trial with 230+ patients is actively recruiting.
The researchers who discovered cannabis could kill cancer cells in the lab explain the science and warn: preclinical evidence is real but no one should replace proven cancer treatments with cannabis.